Author

Julian Panés

EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
EFFICACY AND SAFETY OF ETRASIMOD IN PATIENTS WITH AND WITHOUT CONCOMITANT CORTICOSTEROID TREATMENT IN THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Julian Panés  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR BIOLOGIC/JANUS KINASE INHIBITOR-NAÏVE AND -EXPERIENCED PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Julian Panés  et al.

IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
IMPACT OF PRIOR BIOLOGIC/JANUS KINASE INHIBITOR THERAPY ON THE EFFICACY OF ETRASIMOD: SUBGROUP ANALYSIS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Julian Panés  et al.

ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS
ETRASIMOD 2MG ONCE DAILY AS TREATMENT FOR MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 ELEVATE UC 52 AND ELEVATE UC 12 TRIALS

Julian Panés  et al.

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE–RESPONSE RELATIONSHIPS OF USTEKINUMAB TREATMENT IN PATIENTS WITH CROHN’S DISEASE: RESULTS FROM THE WEEK 48 TREAT TO TARGET VS STANDARD OF CARE ANALYSIS OF THE STARDUST STUDY

Julian Panés  et al.

CORTICOSTEROID-FREE EFFICACY OUTCOMES IN PATIENTS RECEIVING CONCOMITANT CORTICOSTEROIDS AT BASELINE IN THE ETRASIMOD ELEVATE UC 52 TRIAL
CORTICOSTEROID-FREE EFFICACY OUTCOMES IN PATIENTS RECEIVING CONCOMITANT CORTICOSTEROIDS AT BASELINE IN THE ETRASIMOD ELEVATE UC 52 TRIAL

Julian Panés  et al.

ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO
ASSOCIATION BETWEEN EFFICACY OUTCOMES AND PRIOR DURATION OF REMISSION IN PATIENTS WITH ULCERATIVE COLITIS TREATED WITH TOFACITINIB 10 MG TWICE DAILY (BID) WHO WERE IN STABLE REMISSION AND DOSE-REDUCED TO 5 MG BID OR REMAINED ON 10 MG BID: 6-MONTH DATA FRO

Julian Panés  et al.

PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY
PHARMACOKINETICS, IMMUNOGENICITY, AND EXPOSURE-RESPONSE RELATIONSHIP OF USTEKINUMAB IN PATIENTS WITH CROHN'S DISEASE: RESULTS FROM THE WEEK 16 INTERIM ANALYSIS OF THE STARDUST STUDY

Julian Panés  et al.

REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA
REAL-WORLD EXPOSURE-RESPONSE RELATIONSHIP OF VEDOLIZUMAB IN INFLAMMATORY BOWEL DISEASE: A POOLED MULTICENTRE OBSERVATIONAL COHORT ANALYSIS OF CLINICAL AND MODELED PHARMACOLOGICAL DATA

Julian Panés  et al.

EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION
EFFICACY AND SAFETY OF GUSELKUMAB FOR CROHN’S DISEASE THROUGH 3 YEARS: GALAXI-1 LONG-TERM EXTENSION

Julian Panés  et al.

CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY
CLINICALLY ADJUSTED VERSUS THERAPEUTIC DRUG MONITORING DOSING REGIMENS WITH ADALIMUMAB IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE: RESULTS FROM THE SERENE-CD MAINTENANCE STUDY

Julian Panés  et al.

MIRIKIZUMAB-INDUCED TRANSCRIPTOME CHANGES IN PATIENT BIOPSIES AT WEEK 12 ARE MAINTAINED THROUGH WEEK 52 IN PATIENTS WITH ULCERATIVE COLITIS
MIRIKIZUMAB-INDUCED TRANSCRIPTOME CHANGES IN PATIENT BIOPSIES AT WEEK 12 ARE MAINTAINED THROUGH WEEK 52 IN PATIENTS WITH ULCERATIVE COLITIS

Julian Panés  et al.

MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL
MAINTENANCE OF WEEK 12 RESPONSES THROUGH WEEK 52 WITH ETRASIMOD IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC 52 TRIAL

Julian Panés  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATE ON THE ANALYSIS OF MALIGNANCY RATES FROM THE ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: AN UPDATE ON THE ANALYSIS OF MALIGNANCY RATES FROM THE ULCERATIVE COLITIS CLINICAL PROGRAMME AS OF MAY 2019

Julian Panés  et al.

RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN THE TOFACITINIB OCTAVE PHASE 3 INDUCTION AND MAINTENANCE STUDIES
RELATIONSHIP BETWEEN HEALTH-RELATED QUALITY OF LIFE AND WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN THE TOFACITINIB OCTAVE PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Julian Panés  et al.

RELATIONSHIP BETWEEN DISEASE ACTIVITY AS ASSESSED BY THE MAYO SCORE AND WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN THE TOFACITINIB OCTAVE PHASE 3 INDUCTION AND MAINTENANCE STUDIES
RELATIONSHIP BETWEEN DISEASE ACTIVITY AS ASSESSED BY THE MAYO SCORE AND WORK PRODUCTIVITY IN PATIENTS WITH ULCERATIVE COLITIS IN THE TOFACITINIB OCTAVE PHASE 3 INDUCTION AND MAINTENANCE STUDIES

Julian Panés  et al.

TREATMENT PATTERNS OF COMPLEX PERIANAL FISTULA IN CROHN'S DISEASE IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN: THE PREFACE STUDY, A RETROSPECTIVE CHART REVIEW
TREATMENT PATTERNS OF COMPLEX PERIANAL FISTULA IN CROHN'S DISEASE IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN: THE PREFACE STUDY, A RETROSPECTIVE CHART REVIEW

Julian Panés  et al.

TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS
TOFACITINIB FOR THE TREATMENT OF ULCERATIVE COLITIS: UP TO 7.8 YEARS OF SAFETY DATA FROM GLOBAL CLINICAL TRIALS

Julian Panés  et al.

THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY
THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDY

Julian Panés  et al.

THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12
THE EFFECT OF GUSELKUMAB INDUCTION THERAPY ON INFLAMMATORY BIOMARKERS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: QUASAR PHASE 2B INDUCTION RESULTS THROUGH WEEK 12

Julian Panés  et al.

Item 41 - 60 / 71
1 2
3
4